Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | See Remarks | June 01, 2025 | June 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NewAmsterdam Pharma Co N.V.
Report date June 01, 2025 · Filed June 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 55,000 |
Reported balance
After 2025-06-01 transaction · row 1
1 source rowRow 1 · 2025-06-01 · Grant · Acquired 55,000 · Balance 55,000 F1: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2: Each RSU was granted on June 1, 2025 for no consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.11 · Expires 2035-06-01 | Direct | 315,000 |
Reported balance
After 2025-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-01 · Grant · Acquired 315,000 · Balance 315,000 F3: 25% of the shares underlying the option will vest on June 1, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date.
F2: Each RSU was granted on June 1, 2025 for no consideration.
F3: 25% of the shares underlying the option will vest on June 1, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OptiNose, Inc.
Report date May 21, 2025 · Filed May 21, 2025
Section 16 reporting ended · disclosed 2025-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 125,204 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, (i) each outstanding and vested restricted stock unit ("RSU") was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR and (ii) each outstanding and unvested RSU was canceled, with the holder thereof contingently entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR, with such consideration vesting and becoming payable, if at all, at the same time as the unvested RSU would have vested and been payable pursuant to its terms. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.77 · Expires 2035-02-21 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 10,575 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.30 · Expires 2034-02-28 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 9,333 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.75 · Expires 2032-01-11 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-21 · Disposition to issuer · Disposed 16,752 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.50 · Expires 2033-03-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-21 · Disposition to issuer · Disposed 12,350 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.65 · Expires 2031-03-04 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-05-21 · Disposition to issuer · Disposed 5,333 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.15 · Expires 2030-03-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-21 · Disposition to issuer · Disposed 3,056 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $111.30 · Expires 2029-02-28 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-05-21 · Disposition to issuer · Disposed 5,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.00 · Expires 2027-10-12 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-05-21 · Disposition to issuer · Disposed 5,775 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.10 · Expires 2027-01-30 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-05-21 · Disposition to issuer · Disposed 9,626 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.
F3: Pursuant to the Merger Agreement, at the Effective Time, (i) each outstanding and vested restricted stock unit ("RSU") was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR and (ii) each outstanding and unvested RSU was canceled, with the holder thereof contingently entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR, with such consideration vesting and becoming payable, if at all, at the same time as the unvested RSU would have vested and been payable pursuant to its terms.
F4: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2025 Filed Jun 3, 2025 21:02 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 315,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0000950170-25-081087 · ownership.xml · derivative · entry 2 Marino Michael F III · CIK 0001502700 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,000 Underlying: Ordinary Shares · 315,000 shares Expires 2035-06-01 F3 · derivative.exercise_date: 25% of the shares underlying the option will vest on June 1, 2026, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 21:02 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 55,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081087 · ownership.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 F1 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2 · price: Each RSU was granted on June 1, 2025 for no consideration. Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,626 | Not disclosed Strike: $77.10 | Not disclosed |
DisclosureSEC source: 0001104659-25-051350 · tm2515648-5_4seq1.xml · derivative · entry 10 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,626 shares Expires 2027-01-30 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,775 | Not disclosed Strike: $240.00 | Not disclosed |
DisclosureSEC source: 0001104659-25-051350 · tm2515648-5_4seq1.xml · derivative · entry 9 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,775 shares Expires 2027-10-12 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,500 | Not disclosed Strike: $111.30 | Not disclosed |
DisclosureSEC source: 0001104659-25-051350 · tm2515648-5_4seq1.xml · derivative · entry 8 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires 2029-02-28 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,056 | Not disclosed Strike: $81.15 | Not disclosed |
DisclosureSEC source: 0001104659-25-051350 · tm2515648-5_4seq1.xml · derivative · entry 7 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,056 shares Expires 2030-03-06 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,333 | Not disclosed Strike: $52.65 | Not disclosed |
DisclosureSEC source: 0001104659-25-051350 · tm2515648-5_4seq1.xml · derivative · entry 6 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,333 shares Expires 2031-03-04 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,350 | Not disclosed Strike: $28.50 | Not disclosed |
DisclosureSEC source: 0001104659-25-051350 · tm2515648-5_4seq1.xml · derivative · entry 5 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,350 shares Expires 2033-03-08 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,752 | Not disclosed Strike: $27.75 | Not disclosed |
DisclosureSEC source: 0001104659-25-051350 · tm2515648-5_4seq1.xml · derivative · entry 4 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,752 shares Expires 2032-01-11 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,333 | Not disclosed Strike: $27.30 | Not disclosed |
DisclosureSEC source: 0001104659-25-051350 · tm2515648-5_4seq1.xml · derivative · entry 3 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,333 shares Expires 2034-02-28 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,575 | Not disclosed Strike: $5.77 | Not disclosed |
DisclosureSEC source: 0001104659-25-051350 · tm2515648-5_4seq1.xml · derivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,575 shares Expires 2035-02-21 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerCommon Stock | 125,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-051350 · tm2515648-5_4seq1.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2 · price: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, (i) each outstanding and vested restricted stock unit ("RSU") was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR and (ii) each outstanding and unvested RSU was canceled, with the holder thereof contingently entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR, with such consideration vesting and becoming payable, if at all, at the same time as the unvested RSU would have vested and been payable pursuant to its terms. Read SEC document |
| March 18, 2025 Filed Mar 19, 2025 14:48 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 246 | $5.61 | $1,380.06 |
DisclosureSEC source: 0001494650-25-000040 · wk-form4_1742410106.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,038 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 17:31 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 2,145 | $5.29 | $11,347.05 |
DisclosureSEC source: 0001494650-25-000026 · wk-form4_1741127459.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,284 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 21, 2025 Filed Feb 26, 2025 19:59 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 10,575 | $0.00 Strike: $5.77 | $0.00 |
DisclosureSEC source: 0001494650-25-000009 · wk-form4_1740617947.xml · derivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,575 Underlying: Common Stock · 10,575 shares Expires 2035-02-21 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 21, 2025. Twenty-five percent (25%) of the option vests and becomes exercisable on February 21, 2026, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| February 21, 2025 Filed Feb 26, 2025 19:59 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 21,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-25-000009 · wk-form4_1740617947.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,429 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on February 21, 2026, and the balance vests in equal quarterly installments over the remaining three years of the four year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| December 17, 2024 Filed Dec 18, 2024 16:37 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 3,050 | $0.44 | $1,342.00 |
DisclosureSEC source: 0001494650-24-000172 · wk-form4_1734557840.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,188 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 17, 2024 Filed Sep 18, 2024 16:10 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 3,226 | $0.87 | $2,806.62 |
DisclosureSEC source: 0001494650-24-000132 · wk-form4_1726690247.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 547,238 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 17, 2024 Filed Jul 18, 2024 16:22 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 49,408 | $1.14 | $56,325.12 |
DisclosureSEC source: 0001494650-24-000112 · wk-form4_1721334163.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,464 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 18, 2024 Filed Jun 18, 2024 17:12 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 3,267 | $1.19 | $3,887.73 |
DisclosureSEC source: 0001494650-24-000095 · wk-form4_1718745136.xml · nonDerivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,818 F2 · acquired: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units under multiple award agreements. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 15:03 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 2,946 | $1.19 | $3,505.74 |
DisclosureSEC source: 0001494650-24-000097 · wk-form4_1718910211.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 599,872 F1 · acquired: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units under multiple award agreements. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 15, 2024 Filed Jun 18, 2024 17:12 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 3,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-24-000095 · wk-form4_1718745136.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 606,085 F1 · acquired: Represents the vesting of performance-based restricted stock units (Performance RSUs) granted on March 6, 2020. Fifty percent (50%) of the Performance RSUs vested on June 15, 2022, upon achievement of certain milestones in connection with the Company's development programs. The balance vests in eight equal quarterly installments, subject to continued service with the Issuer. Each Performance RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 12:45 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 15,059 | $1.88 | $28,310.92 |
DisclosureSEC source: 0001494650-24-000036 · wk-form4_1710866701.xml · nonDerivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,268 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units under multiple award agreements. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 12:45 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 3,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-24-000036 · wk-form4_1710866701.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 617,327 F1 · shares: Represents the vesting of performance-based restricted stock units (Performance RSUs) granted on March 6, 2020. Fifty percent (50%) of the Performance RSUs vested on June 15, 2022, upon achievement of certain milestones in connection with the Company's development programs. The balance vests in eight equal quarterly installments, subject to continued service with the Issuer. Each Performance RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 16:05 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001494650-24-000010 · wk-form4_1709240704.xml · derivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2034-02-28 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 28, 2024. Twenty-five percent (25%) of the option vests and becomes exercisable on February 28, 2025, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 16:05 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 280,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-24-000010 · wk-form4_1709240704.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 613,511 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on February 28, 2025, and the balance vests in equal quarterly installments over the remaining three years of the four year period, subject to continued service with the Issuer provided that, in the event certain minimum performance criteria related to the net revenue and operating profit of OptiNose, Inc. are achieved, then any unvested RSUs shall become fully-vested subject to the Executive's continued service through such date. Each RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 12:20 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 5,005 | $1.15 | $5,755.75 |
DisclosureSEC source: 0001494650-23-000101 · wk-form4_1703092807.xml · nonDerivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,511 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units under multiple award agreements. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 12:20 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 3,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-23-000101 · wk-form4_1703092807.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,516 F1 · shares: Represents the vesting of performance-based restricted stock units (Performance RSUs) granted on March 6, 2020. Fifty percent (50%) of the Performance RSUs vested on June 15, 2022, upon achievement of certain milestones in connection with the Company's development programs. The balance vests in eight equal quarterly installments, subject to continued service with the Issuer. Each Performance RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 19:04 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 4,991 | $1.37 | $6,837.67 |
DisclosureSEC source: 0001494650-23-000089 · wk-form4_1695164668.xml · nonDerivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,699 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units under multiple award agreements. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 19:04 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 3,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-23-000089 · wk-form4_1695164668.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,690 F1 · shares: Represents the vesting of performance-based restricted stock units (Performance RSUs) granted on March 6, 2020. Fifty percent (50%) of the Performance RSUs vested on June 15, 2022, upon achievement of certain milestones in connection with the Company's development programs. The balance vests in eight equal quarterly installments, subject to continued service with the Issuer. Each Performance RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 13:04 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 1,516 | $1.15 | $1,743.40 |
DisclosureSEC source: 0001494650-23-000071 · wk-form4_1687280642.xml · nonDerivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,873 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units under multiple award agreements. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 13:04 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 3,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-23-000071 · wk-form4_1687280642.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,389 F1 · shares: Represents the vesting of performance-based restricted stock units (Performance RSUs) granted on March 6, 2020. Fifty percent (50%) of the Performance RSUs vested on June 15, 2022, upon achievement of certain milestones in connection with the Company's development programs. The balance vests in eight equal quarterly installments, subject to continued service with the Issuer. Each Performance RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 16:02 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 4,972 | $1.79 | $8,899.88 |
DisclosureSEC source: 0001494650-23-000030 · wf-form4_167934254337199.xml · nonDerivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,573 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units under multiple award agreements. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 15, 2023 Filed Mar 20, 2023 16:02 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 3,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-23-000030 · wf-form4_167934254337199.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,545 F1 · shares: Represents the vesting of performance-based restricted stock units (Performance RSUs) granted on March 6, 2020. Fifty percent (50%) of the Performance RSUs vested on June 15, 2022, upon achievement of certain milestones in connection with the Company's development programs. The balance vests in eight equal quarterly installments, subject to continued service with the Issuer. Each Performance RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 14:42 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 185,250 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001494650-23-000026 · wf-form4_167847734651106.xml · derivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,250 Underlying: Common Stock · 185,250 shares Expires 2033-03-08 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on March 8, 2023. Twenty-five percent (25%) of the option vests and becomes exercisable on March 8, 2024, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 14:42 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 154,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-23-000026 · wf-form4_167847734651106.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,728 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on March 8, 2024, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer provided that, in the event XHANCE is approved by the U.S. FDA for commercialization for the treatment of chronic rhinosinusitis or substantially similar indication, then any unvested RSUs shall become fully-vested on the four month anniversary of such approval, subject to the Executive's continued service through such date. Each RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 09:51 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 5,241 | $1.77 | $9,276.57 |
DisclosureSEC source: 0001494650-23-000006 · wf-form4_167396705240208.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,353 F1 · date: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 13:50 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 2,751 | $1.69 | $4,649.19 |
DisclosureSEC source: 0001494650-22-000144 · wf-form4_167147580008043.xml · nonDerivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,594 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 13:50 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 3,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-22-000144 · wf-form4_167147580008043.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,345 F1 · shares: Represents the grant of performance-based restricted stock units (Performance RSUs) on March 6, 2020. Fifty percent (50%) of the Performance RSUs vested on June 15, 2022, upon achievement of certain milestones in connection with the Company's development programs. The balance vests in eight equal quarterly installments, subject to continued service with the Issuer. Each Performance RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| September 20, 2022 Filed Sep 20, 2022 17:37 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 1,151 | $3.56 | $4,097.56 |
DisclosureSEC source: 0001494650-22-000106 · wf-form4_166370984936629.xml · nonDerivative · entry 3 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,528 F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 17:37 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 1,583 | $3.55 | $5,619.65 |
DisclosureSEC source: 0001494650-22-000106 · wf-form4_166370984936629.xml · nonDerivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,679 F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 15, 2022 Filed Sep 20, 2022 17:37 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 3,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-22-000106 · wf-form4_166370984936629.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,262 F1 · shares: Represents the grant of performance-based restricted stock units (Performance RSUs) on March 6, 2020. Fifty percent (50%) of the Performance RSUs vested on June 15, 2022, upon achievement of certain milestones in connection with the Company's development programs. The balance vests in eight equal quarterly installments, subject to continued service with the Issuer. Each Performance RSU represents the right to receive one share of common stock of OptiNose, Inc. F2 · balance_after: Includes 14,160 shares acquired under the Optinose, Inc. 2017 Employee Stock Purchase Plan on June 30, 2022 at a price of $1.50 Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 16:11 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 10,793 | $3.49 | $37,667.57 |
DisclosureSEC source: 0001494650-22-000081 · wf-form4_165549665293303.xml · nonDerivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,286 F2 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:11 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 30,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-22-000081 · wf-form4_165549665293303.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,079 F1 · shares: Represents the grant of performance-based restricted stock units (Performance RSUs) on March 6, 2020. Fifty percent (50%) of the Performance RSUs vested on June 15, 2022, upon achievement of certain milestones in connection with the Company's development programs. The balance vests in eight equal quarterly installments, subject to continued service with the Issuer. Each Performance RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 13:25 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 4,617 | $2.11 | $9,741.87 |
DisclosureSEC source: 0001494650-22-000031 · wf-form4_164753791093063.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,545 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 16:04 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 166,185 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001494650-22-000008 · wf-form4_164202145152447.xml · derivative · entry 3 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,185 Underlying: Common Stock · 166,185 shares Expires 2026-01-11 F3 · shares: Represents the maximum number of options eligible to vest during the 4-year vesting period subject to the achievement of certain performance-based objectives relating to the trading price of OptiNose, Inc. common stock. If the minimum performance criteria relating to the trading price of OptiNose, Inc. common stock is not achieved, then none of the options will be eligible to vest. F4 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, commencing on January 11, 2022, subject to the achievement of certain performance-based objectives relating to the trading price of OptiNose, Inc. common stock and continued service with the Issuer. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 16:04 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 85,095 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001494650-22-000008 · wf-form4_164202145152447.xml · derivative · entry 2 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,095 Underlying: Common Stock · 85,095 shares Expires 2032-01-11 F2 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on January 11, 2022. Twenty-five percent (25%) of the option vests and becomes exercisable on January 11, 2023, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 16:04 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantCommon Stock | 56,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001494650-22-000008 · wf-form4_164202145152447.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,162 F1 · shares: Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on January 11, 2023, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 09:25 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 580 | $1.64 | $951.20 |
DisclosureSEC source: 0001494650-21-000153 · wf-form4_163975111083997.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,432 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 16, 2021 Filed Sep 17, 2021 13:54 UTC | OptiNose, Inc. OPTN · Entity 79464 | SaleCommon Stock | 578 | $2.79 | $1,612.04 |
DisclosureSEC source: 0001494650-21-000109 · wf-form4_163190124409671.xml · nonDerivative · entry 1 Marino Michael F III · CIK 0001502700 · Chief Legal Officer & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,012 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.